Literature DB >> 23934122

Linking MLL and the HGF-MET signaling pathway in liver cancer.

Jens U Marquardt1, Snorri S Thorgeirsson.   

Abstract

Mixed-lineage leukemia (MLL; also known as myeloid/lymphoid), the human homolog of trithorax in Drosophila, is a transcriptional coactivator that plays an essential role during early development and hematopoiesis. Furthermore, MLL is critically involved in the epigenetic regulation of cell cycle, senescence, DNA damage, and stem cell self-renewal. Chromosomal aberrations of MLL in acute leukemias are well documented, but the role of this gene in solid malignancies remains unclear. In this issue of the JCI, Takeda et al. describe a novel epigenetic link between MLL and the HGF-MET signaling pathway conferring invasive and metastatic properties to hepatocellular carcinoma cells.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23934122      PMCID： PMC3696572          DOI： 10.1172/JCI70235

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  26 in total

Review 1.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Authors:  Helena Linardou; Issa J Dahabreh; Dimitra Kanaloupiti; Fotios Siannis; Dimitrios Bafaloukos; Paris Kosmidis; Christos A Papadimitriou; Samuel Murray
Journal:  Lancet Oncol       Date:  2008-09-17       Impact factor: 41.316

2.  Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.

Authors:  Pal Kaposi-Novak; Ju-Seog Lee; Luis Gòmez-Quiroz; Cédric Coulouarn; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2006-05-18       Impact factor: 14.808

Review 3.  Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies.

Authors:  Jens U Marquardt; Peter R Galle; Andreas Teufel
Journal:  J Hepatol       Date:  2011-07-23       Impact factor: 25.083

4.  Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors.

Authors:  Koji Uchino; Ryosuke Tateishi; Shuichiro Shiina; Miho Kanda; Ryota Masuzaki; Yuji Kondo; Tadashi Goto; Masao Omata; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Cancer       Date:  2011-03-22       Impact factor: 6.860

5.  Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair.

Authors:  Chang-Goo Huh; Valentina M Factor; Aránzazu Sánchez; Koichi Uchida; Elizabeth A Conner; Snorri S Thorgeirsson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-30       Impact factor: 11.205

6.  Hepatocyte-specific c-Met deletion disrupts redox homeostasis and sensitizes to Fas-mediated apoptosis.

Authors:  Luis E Gómez-Quiroz; Valentina M Factor; Pal Kaposi-Novak; Cedric Coulouarn; Elizabeth A Conner; Snorri S Thorgeirsson
Journal:  J Biol Chem       Date:  2008-03-18       Impact factor: 5.157

7.  Scatter factor/hepatocyte growth factor is essential for liver development.

Authors:  C Schmidt; F Bladt; S Goedecke; V Brinkmann; W Zschiesche; M Sharpe; E Gherardi; C Birchmeier
Journal:  Nature       Date:  1995-02-23       Impact factor: 49.962

8.  Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal.

Authors:  Kathryn A McMahon; Samantha Y-L Hiew; Suzana Hadjur; Henrique Veiga-Fernandes; Ursula Menzel; Amanda J Price; Dimitris Kioussis; Owen Williams; Hugh J M Brady
Journal:  Cell Stem Cell       Date:  2007-09-13       Impact factor: 24.633

9.  HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma.

Authors:  Shugaku Takeda; Han Liu; Satoru Sasagawa; Yiyu Dong; Paul A Trainor; Emily H Cheng; James J Hsieh
Journal:  J Clin Invest       Date:  2013-06-24       Impact factor: 14.808

10.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Authors:  Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta
Journal:  Lancet Oncol       Date:  2012-11-20       Impact factor: 41.316
View more
  8 in total

Review 1.  The CRISPR-Cas9 system: a promising tool for discovering potential approaches to overcome drug resistance in cancer.

Authors:  Jiayu Zhang; Wenlong Zhou; Xiaoxuan Wang; Lihui Wang
Journal:  RSC Adv       Date:  2018-09-28       Impact factor: 4.036

2.  Liver cancer oncogenomics: opportunities and dilemmas for clinical applications.

Authors:  Jens U Marquardt; Jesper B Andersen
Journal:  Hepat Oncol       Date:  2015

3.  The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models.

Authors:  Friedhelm Bladt; Manja Friese-Hamim; Christian Ihling; Claudia Wilm; Andree Blaukat
Journal:  Cancers (Basel)       Date:  2014-08-19       Impact factor: 6.639

Review 4.  The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?

Authors:  Marjorie Boissinot; Mathias Vilaine; Sylvie Hermouet
Journal:  Cancers (Basel)       Date:  2014-08-12       Impact factor: 6.639

5.  Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing.

Authors:  Song Wu; Zhao Yang; Rui Ye; Dan An; Chong Li; Yitian Wang; Yongqiang Wang; Yi Huang; Huan Liu; Feida Li; Luyun He; Da Sun; Yuan Yu; Qiaoling Li; Peide Huang; Meng Zhang; Xin Zhao; Tengteng Bi; Xuehan Zhuang; Liyan Zhang; Jingxiao Lu; Xiaojuan Sun; Fangjian Zhou; Chunxiao Liu; Guosheng Yang; Yong Hou; Zusen Fan; Zhiming Cai
Journal:  Oncotarget       Date:  2016-01-19

Review 6.  Epigenetic regulation of histone H3 in the process of hepatocellular tumorigenesis.

Authors:  Dan Li; Zhenguo Zeng
Journal:  Biosci Rep       Date:  2019-08-02       Impact factor: 3.840

7.  TASP1 Promotes Gallbladder Cancer Cell Proliferation and Metastasis by Up-regulating FAM49B via PI3K/AKT Pathway.

Authors:  Yijian Zhang; Pengcheng Du; Yang Li; Qin Zhu; Xiaoling Song; Shibo Liu; Jiaqi Hao; Liguo Liu; Fatao Liu; Yunping Hu; Lin Jiang; Qiang Ma; Wei Lu; Yingbin Liu
Journal:  Int J Biol Sci       Date:  2020-01-14       Impact factor: 6.580

8.  Correlations of microvascular blood flow of contrast-enhanced ultrasound and HGF/c-Met signaling pathway with clinicopathological features and prognosis of patients with hepatocellular carcinoma.

Authors:  Peng-Hui Zhuang; Lei Xu; Lu Gao; Wei Lu; Li-Tao Ruan; Jin Yang
Journal:  Onco Targets Ther       Date:  2017-02-14       Impact factor: 4.345
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.